Science 37 – Making the promise of virtual trials the new reality by connecting patients with doctors through telemedicine visits and integrated logistics

Research studies, surveys, focus groups, and one-on-one conversations have consistently found that some of the biggest barriers to trial participation are time and travel. Forcing patients – many of whom are living with chronic or life-threatening conditions to spend hours traveling to trial sites for appointments and treatments is burdensome and interferes with their overall quality of life. This reduces their willingness to participate and increases the chance that they will drop out before the trial is completed. Virtual trials were developed to address these issues and the technology makes it possible. By enabling primary investigators to complete some or all visits via telemedicine, and to collect patient data automatically from connected devices and communication platforms, they are able to make participation far less time-consuming and more enjoyable. These models are equally beneficial for sponsors. By starting with the patients’ needs and designing trials from their viewpoint, sponsors can experience significant time and cost savings.

Science 37 is making the more complex virtual trials the reality. By engaging with patients from the comfort of their own home, the firm provides access to patients who can never be reached by traditional site-based models. It has proven to enroll faster, retain patients at a higher rate, and reach a more representative population. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses, who are supported by the industry’s most comprehensive, fully integrated, decentralized clinical trial platform.

Top-notch services offered by Science 37

Virtual Trials: Its signature virtual or decentralized trial model has proven to enroll faster, retain patients longer, and reach a more diverse and representative patient population. It helps you to leverage the full power of the Science 37 model from protocol design to database lock. One can conduct patient visits affordably via Science 37’s telemedicine investigators and provide expert home health services from its mobile nurse community. It’s all choreographed by the industry’s most advanced technology platform, which seamlessly orchestrates the entire experience.

Science 37 Metasite: The traditional, site-based approach to clinical research restricts your access to patient populations, simply by its limited geographic reach, often only 5% of the total patient population. With Science 37 acting as an additional site within your network, you will gain access to the remaining 95% of the total patient population not served by your traditional site network, while collecting the exact same study data in a more efficient manner. You’ll also gain learning of the virtual model for use in future development, and de-risk your study from unforeseen issues like today’s pandemic to ensure business continuity.

Science 37 Platform: While Science 37 has unrivaled experience orchestrating decentralized clinical trials, the platform is what makes it all possible. It enables your research using the platform that has fueled more decentralized trials than any other on the planet. You’ll get comprehensive, end-to-end trial management using this fully configurable system, which is available as a standalone solution or coupled with its various suites of services.

The stalwart behind the supremacy of Science 37

David Coman is the Chief Executive Officer of Science 37. Prior joining Science 37 he worked at ERT, where he led its data and analytics business after serving as the company’s chief strategy officer. As the leader of ERT’s data and analytics business, he reimagined the way the pharmaceutical industry looks at performance and risk management for clinical trials while more than doubling the company’s bookings from analytics over a two-year period. In his strategy role, Mr. David spearheaded the acquisition of four companies in a 12-month period, generating more than $1 billion in enterprise value, while repositioning ERT as the market leader in clinical trial data generation.

Mr. David joined ERT from Quintiles (now IQVIA), where as chief marketing officer and founder of its Digital Patient business, he helped lead the company’s growth from $2.7 billion in 2007 to $4.3 billion in 2015. It was here that he pioneered some of the industry’s first decentralized clinical trials while also driving significant growth and enterprise value. Mr. David earned his B.A. in advertising from Michigan State University and his MBA in marketing, entrepreneurship, and finance from the Kellogg Graduate School of Management at Northwestern University.

“We make clinical research more human and accessible. We offer a range of services to help you stay flexible across therapeutic areas.”